Search clinical trials for: Antibodies, Monoclonal

Total 3745 results

Huazhong University of Science and Technology

Unknown

PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT

HCC

China
Merck KGaA, Darmstadt, Germany

Completed

A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies

Psoriasis

United Kingdom
Abbott

Terminated

Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma | Metastases

United States
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Melanoma | Urothelial Carcinoma | Renal Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers

Healthy
Ludwig Institute for Cancer Research
Medarex

Terminated

A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

Synovial Sarcoma

United States
National Cancer Institute (NCI)

Completed

Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Noncontiguous Stage II Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic... and other conditions

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After Transplantation

Patients With Recurrent Acute Myelogenous Leukemia After Transplantation

China
Xijing Hospital

Not yet recruiting

RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer
Institute of Hematology & Blood Diseases Hospital...
Henan Cancer Hospital; Beijing Children's Hospital; Tianjin Medical University... and other collaborators

Recruiting

TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)

China
M.D. Anderson Cancer Center

Active, not recruiting

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Recurrent T-Cell Prolymphocytic Leukemia | T-Cell Prolymphocytic Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Locally Advanced Angiosarcoma | Metastatic Angiosarcoma | Recurrent Angiosarcoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Acute Leukemia | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Systemic Mastocytosis | Recurrent Hematologic Malignancy | Hairy Cell Leukemia | Chronic... and other conditions
Genzyme, a Sanofi Company

Completed

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Focal Segmental Glomerulosclerosis

United States, Germany, United Kingdom, Italy
Novartis

Terminated

Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis

Rheumatoid Arthritis

Germany, Belgium, Netherlands, Poland
Shanghai Celfuture Biotech Co., Ltd.

Not yet recruiting

A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Colorectal Cancer

China
Beijing Friendship Hospital

Recruiting

Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer

Colorectal Neoplasms

China
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaborators

Completed

3BNC117 and 10-1074 in ART-treated Individuals

Human Immunodeficiency Virus

United States
Facet Biotech

Completed

A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease

Crohn's Disease | Colitis | Digestive System Disease | Gastrointestinal Disease | Intestinal Disease

United States, Canada
Hoffmann-La Roche

Terminated

A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)

Alzheimer Disease

United States, Korea, Republic of, Canada, Spain, Belgium, France, Japan, Brazil, United Kingdom, Poland, Australia, Germany, Peru, Russian Federation, Denmark, Hungary, Italy, Netherlands, Sweden, Argentina, Chile, Mexico, China, Fin... and more
MorphoSys AG

Completed

Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria, Germany, Netherlands, Poland, Ukraine
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Lee's Pharmaceutical Limited

Recruiting

A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer

Cervical Cancer

China
Lee's Pharmaceutical Limited

Recruiting

A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
CStone Pharmaceuticals

Completed

A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
MedImmune LLC
Cambridge Antibody Technology

Suspended

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

United States
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
LiNing

Not yet recruiting

The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer

Colorectal Neoplasms

China
Johns Hopkins University

Recruiting

Human Penile Allotransplantation

Wounds and Injuries | Amputation | Amputation, Traumatic | Urologic Surgical Procedures, Male | Amputation, Traumatic/Surgery | Penis/Transplantation | Penis/Surgery | Penis/Injuries

United States
Merck KGaA, Darmstadt, Germany

Terminated

ChangE From Any Systemic psoriasiS therapY to Raptiva (EASY)

Chronic Plaque Psoriasis

Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer

Colorectal Cancer | Metastatic Cancer

United States
Cambridge Antibody Technology

Unknown

Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease (NHL)

Leukemia | Non-Hodgkin's Lymphoma | NHL

United States, Poland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Minimal Residual Disease | Adult Acute Lymphoblastic Leukemia in Complete Remission

United States
University of Mostar

Completed

Prognostic Value of Protein IMP3 Expression in Cervical Cancer

Cervical Carcinoma
Jacobio Pharmaceuticals Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Solid Tumor

China
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
Cancer Research Institute of Contra Costa

Completed

Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

Breast Cancer

United States
Universita di Verona

Completed

Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis

Psoriasis Vulgaris

Italy
Hoffmann-La Roche

Completed

A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers

Healthy Volunteer

United States
Genzyme, a Sanofi Company

Completed

Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, Belgium
Peking University
CARsgen Therapeutics Co., Ltd.

Completed

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Advanced Solid Tumor

China
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

United States
Beijing VDJBio Co., LTD.

Recruiting

A Study of Anti-IL-6R mAb Injection in Patients With iMCD

Idiopathic Multicentric Castleman's Disease

China
Chen Xiaoping

Not yet recruiting

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

HCC
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

Cholangiocarcinoma | Liver and Intrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Gallbladder Cancer AJCC v7 | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IV Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage... and other conditions

United States
Chen Xiaoping

Completed

VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

Recurrence | HCC

China
St George's, University of London

Unknown

Study of Single IV Administration of P2G12 (FuturePharma)

HIV Infection

United Kingdom
Eli Lilly and Company
Versanis Bio, Inc.

Active, not recruiting

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

Obesity | Obese | Overweight or Obesity

United States, Australia, New Zealand

Search clinical trials for: Antibodies, Monoclonal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations